As the medical community has learned, COVID-19 can dramatically impact the GI tract from abdominal pain to loss of appetite to diarrhea. So, what does that mean for people suffering from inflammatory bowel disease (IBD)? AGA’s free course, APP Pharmacology: IBD Series – Biologics, reviews the GI field’s current understanding about COVID-19, its impact on IBD patients and current treatment guidelines on the virus. In addition, the course focuses on key biologic and oral small-molecule treatments for IBD. Learn the dosing, pharmacokinetics and side effects for:
- TNF antagonist (anti-TNF).
- Janus Kinase (JAK) inhibitor.
Led by nationally-recognized clinical nurse practitioners, you will be guided through case-based scenarios designed to help you identify which biologic therapies are best suited for your patients. And, as your expertise grows, so will your value to your patient care team.
This program was supported by independent educational grants from Gilead Sciences, Inc. and Takeda Pharmaceuticals U.S.A., Inc.